Korean red ginseng

ApprovedSmall molecule

SShanghai Jiao Tong University School of Medicine

Korean red ginseng is one of 42 small molecule programs targeting Essential Hypertension. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Essential HypertensionActive, not recruiting

Male InfertilityActive, not recruiting

Essential HypertensionPhase 2

Active, not recruiting

Male InfertilityApproved

Active, not recruiting

Competition

Competitive Landscape

238 competitors in Essential Hypertension

#DrugCompanyPhaseTrials

Edarbi

Takeda

Phase 3

12 2

Benicar

Novartis

Phase 3

6 3

Edarbi

Takeda

Phase 3

3 4

Avapro

Sanofi

Phase 3

2 5

Micardis

Boehringer Ingelheim

Phase 3

10 6

Crestor

AstraZeneca

Phase 3

1 7

Thalitone

Alnylam Pharmaceuticals

Phase 3

1 8

Benicar

CCosette Pharmaceuticals, Inc.

Phase 3

8 9

Atacand

IIstituto Clinico Humanitas

Phase 3

7 10

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypersensitivity1 trial

Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet

Completed·TThe Korean Society of Ginseng·Phase 4·NCT01664156·80 enrolled

Elderly1 trial

Effect of Korean Red Ginseng on Oxidation in Middle-aged and Elderly Sub-health Population

Completed·SShanghai Jiao Tong University School of Medicine·Phase 2/3·NCT05592093·900 enrolled

Essential Hypertension1 trial

Effect of Korean Red Ginseng on Central Blood Pressure in Patient With Essential Hypertension

Completed·—·Phase 2·NCT02211352·58 enrolled

Male Infertility1 trial

Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical Study

Completed·PPusan National University Hospital·Phase 4·NCT02204826·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Korean red ginseng. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Korean red ginseng compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Korean red ginseng. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Jiao Tong University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SShanghai Jiao Tong University School of Medicine

Korean red ginseng

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypersensitivity1 trial

Elderly1 trial

Essential Hypertension1 trial

Male Infertility1 trial

References

Drug Info

Quick Facts

Related News